您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 皮肤科药物->牛皮癣
处方药:处方药
包装规格: 4毫升
计价单位:
   
生产厂家英文名:
ANACOR PHARMS INC
该药品相关信息网址1:
http://www.anacor.com/an2690.php
该药品相关信息网址2:
http://investor.anacor.com/releasedetail.cfm?ReleaseID=858211
原产地英文商品名:
KERYDIN 5% TOPICAL SOLUTION 4ml
原产地英文药品名:
TAVABOROLE
中文参考商品译名:
KERYDIN 5% 外用溶液4毫升
中文参考药品译名:
TAVABOROLE
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Onychomycosis
临床试验期:
完成
中文适应病症参考翻译1:
红色毛癣菌、石膏样毛癣菌引起的脚趾灰指甲
药品信息:
Anacor制药公司表示,美国食品和药物管理局批准了其用于治疗趾甲真菌感染的药物Kerydin。 该公司7月8日表示,Kerydin是一款外用药液,预计最早可于本季度在美国推出。 一个月之前加拿大制药商Valeant国际公司的药物Jublia刚刚获得美国批准。 7月8日的早盘交易中Anacor的股价下跌了近11%。 去年Kerydin的有效试验数据显示其较Jublia疗效更低,该公司的股票因此出现暴跌。这两种药物的目标是一致的,即“彻底治愈”,让指甲没有一丝真菌感染。其中最常见的指甲感染是灰指甲,复发率很高。 证券公司Wedbush分析师预测该药明年在美国的销售额为1600万美元,到2021年将达到3.47亿美元的销售高峰。 Anacor表示,灰指甲会导致指甲变形、变色以及甲床分离,在美国影响约35万人。 Anacor公司位于加利福尼亚州的帕洛阿尔托,在早盘晚些时候收复了股市的部分失地,降幅到7%至15.59美元。 商品名:Kerydin 通用名:tavaborole 中文名: 药企:Anacor Pharmaceuticals 适应症:红色毛癣菌、石膏样毛癣菌引起的脚趾灰指甲。 剂型规格:本品为5%局部用溶液。 作用机理:tavaborole是恶硼唑类抗菌药,能够抑制真菌tRNA合成酶,阻断真菌蛋白质合成。 临床试验:两项临床试验共入组了1194例患者,试验1中tavaborole组、对照组治愈率分别为6.5%、0.5%,试验2中tavaborole组、对照组治愈率分别为9.1%、1.5%。 不良反应:涂用部位脱落(2.7%)、红斑(1.6%)、皮炎(1.3%)、嵌甲(2.5%)。 补充说明:tavaborole是FDA今年批准的第二个灰指甲药物,6月6日批准了艾氟康唑,治愈率都是半斤八两低得可怜,患者可以一种一种地尝试。 Anacor Pharmaceuticals said the United States Food and Drug Administration approved the drug for the treatment of toenail fungus Kerydin infection. The company said on July 8, Kerydin is a topical liquid, expected as early as this quarter in the U.S. launch. Month before Canadian drugmaker Valeant International drug Jublia just won American approval. In early trading on July 8 in Anacor's shares fell nearly 11 percent. Last valid test data Kerydin display its lower efficacy than the Jublia, resulting in the company's stock plummeted. Both drugs target is consistent, that is, "completely cured," so that no trace of nail fungal infection. One of the most common nail infection is onychomycosis, a high relapse rate. Wedbush Securities analyst forecasts drug sales next year in the United States for $ 16 million, to 2021 will reach peak sales of $ 347 million. Anacor said fingernail onychomycosis cause deformation, discoloration and separation of the nail bed, affecting about 35 million people in the United States. Anacor company located in Palo Alto, California, later in the morning the stock market recovered some lost ground, down to 7 percent to $ 15.59. Product name: Kerydin Common name: tavaborole Chinese name: Pharmaceutical companies: Anacor Pharmaceuticals   Indications: Trichophyton rubrum, Trichophyton caused plaster-like toe nail fungus.   Formulation specifications: This product is 5% topical solution. Mechanism: tavaborole is evil boron azole antimicrobial drugs, can inhibit fungal tRNA synthetase, blocking the fungal protein synthesis.   Clinical trials: two clinical trials enrolled a total of 1194 cases of patients 1 tavaborole test group and the control group cure rates were 6.5%, 0.5%, 2 tavaborole test group and the control group cure rates were 9.1%, 1.5% .   Adverse reactions: painted with parts off (2.7%), erythema (1.6%), dermatitis (1.3%), ingrown toenails (2.5%).   Additional information: tavaborole is the second year the FDA approved the drug onychomycosis, June 6 approved Ai fluconazole, the cure rate is much to choose pitifully low, the patient may be a kind of try.
更新日期: 2015-04-15
附件:
2014101219531019.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com